HIV Drug Soon to Be Discontinued

The anticipated final date for availability to patients is October 2018.

The Food and Drug Administration (FDA) has posted a notice regarding the availability of Rescriptor Tablets (delavirdine mesylate; ViiV Healthcare). The manufacturer has decided to discontinue the product based on a business decision and not for safety reasons.